Clinical Trial Update: Maintenance Rituximab With mTor Inhibition After High-dose Consolidative Therapy in Lymphoma [Phase 2]

View source ↗

Summary

Phase 2 trial assessing maintenance rituximab combined with mTOR inhibition after high-dose consolidative therapy in various B-cell lymphomas; trial completed w…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gray Zone Lymphoma
• Hodgkin Disease
• Mantle Cell Lymphoma
• Non-mantle Cell Low Grade Cell Lymphomas
• Transformed Lymphoma Dlbcl Pmbcl

Drugs mentioned

• Rituximab (rituximab)
• mTOR inhibitor

Snippet

Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Conditions: CD20+, B-cell Lymphomas, Mantle Cell Lymphoma | Phase 2 | Status: COMPLETED | Results posted: 2018-12-26